ADC Therapeutics

ADC Discontinues Zynlonta Trial in DLBCL After Seven Deaths
ADC Discontinues Zynlonta Trial in DLBCL After Seven Deaths
BioSpace
ADC Therapeutics
Zynlonta
diffuse large B-cell lymphoma
clinical trials
Flag link:
ADC Therapeutics Halts Enrollment of Zynlonta Trial After Seven Patient Deaths
ADC Therapeutics Halts Enrollment of Zynlonta Trial After Seven Patient Deaths
BioSpace
ADC Therapeutics
Zynlonta
clinical trials
patient deaths
diffuse large B-cell lymphoma
Flag link:
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
BioSpace
layoffs
Rain Oncology
Takeda
PTC Therapeutics
Affimed
Urovant Sciences
Roche
Novavax
Gossamer Bio
Bristol Myers Squibb
ADC Therapeutics
Flag link:
ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug
ADC Therapeutics cuts deal with Sobi to broaden reach of cancer drug
BioPharma Dive
ADC Therapeutics
Sobi
Zylonta
cancer
Europe
Flag link:
EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout
EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout
Pharmaforum
ADC Therapeutics
antibody-drug conjugate
camidanlumab tesirine
EMA
relapsed or refractory Hodgkins lymphoma
Flag link:
EHA 2022 preview – some good news at last
EHA 2022 preview – some good news at last
EP Vantage
EHA
Caribou Biosciences
CB-010
Gracell
Autolus
Roche
Curocell
ADC Therapeutics
Mustang Bio
Flag link:
ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy
ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy
MedCity News
ADC Therapeutics
HealthCare Royalty Partners
Zynlonta
large cell B-cell lymphoma
Flag link:
ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal
ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal
Endpoints
ADC Therapeutics
Zynlonta
Cami
camidanlumab tesirine
Flag link:
ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate
ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate
Biopharma Reporter
ADC Therapeutics
Zynlonta
antibody-drug conjugate
FDA
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
FDA sets May date for verdict on ADC’s lymphoma drug Lonca
FDA sets May date for verdict on ADC’s lymphoma drug Lonca
Pharmaforum
ADC Therapeutics
Lonca
diffuse large B-cell lymphoma
FDA
priority review
Flag link:
ADC gets priority review for anti-CD19 blood cancer drug
ADC gets priority review for anti-CD19 blood cancer drug
Fierce Biotech
FDA
ADC Therapeutics
antibody-drug conjugate
Lonca
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
IPO, check: Now, ADC Therapeutics files for lonca approval
IPO, check: Now, ADC Therapeutics files for lonca approval
Fierce Biotech
ADC Therapeutics
IPOs
FDA
loncastuximab
diffuse large B-cell lymphoma
Flag link:
What pandemic? Biotech floats break records
What pandemic? Biotech floats break records
EP Vantage
biotech
IPOs
ADC Therapeutics
Akouos
Applied Molecular Transport
Avidity Biosciences
Ayala Pharmaceuticals
Forma Therapeutics
Fusion Pharmaceuticals
Generation Bio
Hyloris Pharmaceuticals
Lantern Pharma
ORIC Pharmaceuticals
Pliant Therapeutics
PolyPid
Repare Therapeutics
Royalty Pharma
SutroVax
Flag link:
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals
Endpoints
ADC Therapeutics
IPOs
FDA
Cami
Hodgkin's lymphoma
Flag link:
ADC Therapeutics sets IPO terms, to be valued at up to $1 billion
ADC Therapeutics sets IPO terms, to be valued at up to $1 billion
Marketwatch
ADC Therapeutics
IPOs
cancer
Switzerland
Flag link:
One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again
One IPO attempt pulled, a drug on partial hold and a pandemic, but ADC tries again
Fierce Biotech
ADC Therapeutics
IPOs
COVID-19
loncastuximab
diffuse large B-cell lymphoma
Flag link:
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street
Xconomy
IPOs
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
ADC Therapeutics
Monopar Therapeutics
Flag link:
Led by BioNTech, six biotechs line up for October IPOs
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Flag link:
Does amount matter when it comes to a biotech IPO?
Does amount matter when it comes to a biotech IPO?
EP Vantage
IPOs
biotech
NASDAQ
BioNTech
ADC Therapeutics
Flag link:
Swiss biotech ADC Therapeutics guns for $150M IPO
Swiss biotech ADC Therapeutics guns for $150M IPO
Fierce Biotech
ADC Therapeutics
IPOs
cancer
antibody-drug conjugate
Flag link:

Pages